方正大新药业有限公司发展战略研究
|
摘要
为了进一步提高大新药业公司的市场竞争能力,以求在激烈的市场竞争中确保公司顺利的发展,有必要对公司的经营战略进行认真的研究与分析,以期寻找到适合行业发展环境,能够充分适应国内外市场的竞争策略,给大新药业公司带来强大的竞争力。本文运用SWOT方法、模糊综合评价方法、多元线性回归方法等,结合大新药业的发展历史和近5年的经营现状,立足于目前国内外原料药的竞争及发展现状与趋势,对大新药业企业内外部环境、资源能力等影响企业竞争力的因素进行了分析、评价,由此对大新药业发展战略进行研究。
As increasing the market competitiveness of DaXin pharmaceutical company further in an attempt to make sure the well-off development in the intense market competition, it is essential to research and analyze the operating strategy of the company. Find out the competition strategy which suits development environment and can suit the competition strategy of market at home and abroad, and it will bring the powerful competition for DaXin pharmaceutical company. With the application of SWOT method, fuzzy comprehensive evaluation method, multiple linear regression method, etc., the paper combines the development history of DaXin pharmaceutical and the current situation of recent five years. Moreover, this paper analyzes and evaluates the factors which impacts enterprise competitiveness of DaXin pharmaceutical, such as internal and external environment factors and resource capacity, and studies the developmental strategy of DaXin Pharmaceutical at last.
As increasing the market competitiveness of DaXin pharmaceutical company further in an attempt to make sure the well-off development in the intense market competition, it is essential to research and analyze the operating strategy of the company. Find out the competition strategy which suits development environment and can suit the competition strategy of market at home and abroad, and it will bring the powerful competition for DaXin pharmaceutical company. With the application of SWOT method, fuzzy comprehensive evaluation method, multiple linear regression method, etc., the paper combines the development history of DaXin pharmaceutical and the current situation of recent five years. Moreover, this paper analyzes and evaluates the factors which impacts enterprise competitiveness of DaXin pharmaceutical, such as internal and external environment factors and resource capacity, and studies the developmental strategy of DaXin Pharmaceutical at last.
引文
[1]重庆大新药业股份有限公司网站,www.daxinpharm.com.
[2]汤德平,陶锐,项江繁.原料药产业现状和发展趋势[J].上海医药,2007,28(1):23-26.
[3]蔡德山,覃祖权.国内外原料药市场概况与竞争战略浅析[J].中国制药信息,2002,18(6):31-35.
[4]王高玲.我国原料药行业的SWOT分析及战略选择[J].上海医药,2006,27(10):448-451.
[5]王韧.国内外医药工业及原料药的发展现状与趋势[J].医药中间体及其化工原料,2004,(1):1-4.
[6]Omta,S.W.F..A management control perspective an industrial pharmaceutical R&D[J].System Sciences,1995,3:552-562.
[7]Miyazaki,K..Analysis of R&D globalization and public sector linkages in Japanese firms in the 1990s:the case of electronics and pharmaceuticals[J].Management of Innovation and Technology,2000,1:253-258.
[8]青霉素类药物市场表现长久不衰 中高端竞争激烈[J].中国医药报,2005,3(27).
[9]唐书麟.以企业文化建设提升企业核心竞争力[J].企业经济,2003,10
[10]Potdar,Manohar.Applications of RFID in Pharmaceutical Industry[J].Industrial Technology,2006,12:2860-2865.
[11]Ning Chen,Shuo Huang.Pharmaceutical E-Business in China:a Case of a Pharmaceutical E-Commerce Company[J].Service Systems and Service Management,2006,1:361-367.
[12]Da Silva,J.F..Study on the competitiveness of the Brazilian pharmaceutical industry based on Porter's typology[J].Management of Engineering and Technology,2001,2:693-703.
[13]许开立,王永久,陈宝智.多目标模糊评价模型与评价等级计算方法[J].东北大学学报,2001,22(5):558-561.
[14]吴应宇.企业可持续竞争能力系统评价指标体系研究[J].会计研究,2003,(7)
[15]官学梅.我国中小企业核心竞争力及评价体系的研究[D].北京:中国地质大学,2004.
[16]刘智,端木京顺,王强.基于熵权多目标决策的方案评估方法研究[J].数学的实践与认识,2005,35(10):114-119.
[17]黄元生,张洁,邢金峰.火电厂项目决策的综合评价方法研究[J].中国动力工程 学会,2003,14(5):134-137.
[18]杨惠敏,付萍.基于熵权的多级模糊综合评价的应用[J].华北电力大学学报,2005(5):104-107.
[19]胡永宏,贺思辉.综合评价方法[M].北京:科学出版社,2000.
[20]韩主君,汪培庄.应用模糊数学[M].北京:首都经济贸易大学出版社,1998.
[21]郭亚军.综合评价理论与方法[M].北京:科学出版社,2002.
[22](美)迈克波特,陈小说译.竞争战略[M].北京:华夏出版社,1997.
[23]陈敬.我国医药企业发展战略选择[J].中国药房,2002,13(1):35-37.
[24]郭胜民、范晓雯.我国制药企业发展思路的探讨[J].上海医药,1999,20(4):127-131.
[25]严朝贵.我国医药市场动向分析[J].上海医药,1999,20(8):43-46.
[26]王淑玲.医药企业如何进一步开发人力资源[J].中国药业,2002,11(5):56-59.
[27]孙杰、张锐、许陶.全球化背景下中国医药产业的发展策略[J].商业研究,2005(4):36-39.
[28]李思成、温德良.我国医药行业现状与发展趋势[J].中国药房,2003,14(3):77-80.
[29]郭胜民、范晓雯.我国制药企业发展思路的探讨[J].上海医药,1999,20(4):46-47.
[30]王旭深.中国医药行业现状及发展趋势[J].第一军医大学分校学报,2005,28(1):33-35.
[31]陈敬.我国医药企业发展战略选择[J].中国药房,2002,13(1):16-19.
[32]王淑玲.医药企业如何进一步开发人力资源[J].中国药业,2002,11(5):86-89.
[33]吴翠玲等.对生物医药产业可持续发展战略的思考[J].中国生物工程杂志,2002,23(1):124-127.
[34]张蕊.生物制药产业现状分析及我国企业的发展战略[J].工业工程与管理,2005,5:74-76.
[35]田澎.中国世界生物医药产业发展特点及趋势[J].中国药业,2005,14(9):117-119.
[36]张小雨、张震.我国医药业发展的契机[J].齐鲁药事,2005.12:86-89.
[37]Niuwenyuan,etal.Spatial system approach to sustainable development[J].Environmental Management,1995,17(2):352-355.
[38]Goldsmith E.A bluement for Survival London[J].Ecosystems Ltd.,1972,4:442-445.
[39]Madow S D.H.etal.The Limits to Growth London[J].Pan book,1972,6:211-215.
[40]Miyazaki,K..Analysis of R&D globalization and public sector linkages in Japanese firms in the 1990s:the case of electronics and pharmaceuticals[J].Management of Innovation and Technology,2000,1:253-258.
[41]Ning Chen,Shuo Huang.Pharmaceutical E-Business in China:a Case of a Pharmaceutical E-Commerce Company[J].Service Systems and Service Management,2006,1:361-367.
[2]汤德平,陶锐,项江繁.原料药产业现状和发展趋势[J].上海医药,2007,28(1):23-26.
[3]蔡德山,覃祖权.国内外原料药市场概况与竞争战略浅析[J].中国制药信息,2002,18(6):31-35.
[4]王高玲.我国原料药行业的SWOT分析及战略选择[J].上海医药,2006,27(10):448-451.
[5]王韧.国内外医药工业及原料药的发展现状与趋势[J].医药中间体及其化工原料,2004,(1):1-4.
[6]Omta,S.W.F..A management control perspective an industrial pharmaceutical R&D[J].System Sciences,1995,3:552-562.
[7]Miyazaki,K..Analysis of R&D globalization and public sector linkages in Japanese firms in the 1990s:the case of electronics and pharmaceuticals[J].Management of Innovation and Technology,2000,1:253-258.
[8]青霉素类药物市场表现长久不衰 中高端竞争激烈[J].中国医药报,2005,3(27).
[9]唐书麟.以企业文化建设提升企业核心竞争力[J].企业经济,2003,10
[10]Potdar,Manohar.Applications of RFID in Pharmaceutical Industry[J].Industrial Technology,2006,12:2860-2865.
[11]Ning Chen,Shuo Huang.Pharmaceutical E-Business in China:a Case of a Pharmaceutical E-Commerce Company[J].Service Systems and Service Management,2006,1:361-367.
[12]Da Silva,J.F..Study on the competitiveness of the Brazilian pharmaceutical industry based on Porter's typology[J].Management of Engineering and Technology,2001,2:693-703.
[13]许开立,王永久,陈宝智.多目标模糊评价模型与评价等级计算方法[J].东北大学学报,2001,22(5):558-561.
[14]吴应宇.企业可持续竞争能力系统评价指标体系研究[J].会计研究,2003,(7)
[15]官学梅.我国中小企业核心竞争力及评价体系的研究[D].北京:中国地质大学,2004.
[16]刘智,端木京顺,王强.基于熵权多目标决策的方案评估方法研究[J].数学的实践与认识,2005,35(10):114-119.
[17]黄元生,张洁,邢金峰.火电厂项目决策的综合评价方法研究[J].中国动力工程 学会,2003,14(5):134-137.
[18]杨惠敏,付萍.基于熵权的多级模糊综合评价的应用[J].华北电力大学学报,2005(5):104-107.
[19]胡永宏,贺思辉.综合评价方法[M].北京:科学出版社,2000.
[20]韩主君,汪培庄.应用模糊数学[M].北京:首都经济贸易大学出版社,1998.
[21]郭亚军.综合评价理论与方法[M].北京:科学出版社,2002.
[22](美)迈克波特,陈小说译.竞争战略[M].北京:华夏出版社,1997.
[23]陈敬.我国医药企业发展战略选择[J].中国药房,2002,13(1):35-37.
[24]郭胜民、范晓雯.我国制药企业发展思路的探讨[J].上海医药,1999,20(4):127-131.
[25]严朝贵.我国医药市场动向分析[J].上海医药,1999,20(8):43-46.
[26]王淑玲.医药企业如何进一步开发人力资源[J].中国药业,2002,11(5):56-59.
[27]孙杰、张锐、许陶.全球化背景下中国医药产业的发展策略[J].商业研究,2005(4):36-39.
[28]李思成、温德良.我国医药行业现状与发展趋势[J].中国药房,2003,14(3):77-80.
[29]郭胜民、范晓雯.我国制药企业发展思路的探讨[J].上海医药,1999,20(4):46-47.
[30]王旭深.中国医药行业现状及发展趋势[J].第一军医大学分校学报,2005,28(1):33-35.
[31]陈敬.我国医药企业发展战略选择[J].中国药房,2002,13(1):16-19.
[32]王淑玲.医药企业如何进一步开发人力资源[J].中国药业,2002,11(5):86-89.
[33]吴翠玲等.对生物医药产业可持续发展战略的思考[J].中国生物工程杂志,2002,23(1):124-127.
[34]张蕊.生物制药产业现状分析及我国企业的发展战略[J].工业工程与管理,2005,5:74-76.
[35]田澎.中国世界生物医药产业发展特点及趋势[J].中国药业,2005,14(9):117-119.
[36]张小雨、张震.我国医药业发展的契机[J].齐鲁药事,2005.12:86-89.
[37]Niuwenyuan,etal.Spatial system approach to sustainable development[J].Environmental Management,1995,17(2):352-355.
[38]Goldsmith E.A bluement for Survival London[J].Ecosystems Ltd.,1972,4:442-445.
[39]Madow S D.H.etal.The Limits to Growth London[J].Pan book,1972,6:211-215.
[40]Miyazaki,K..Analysis of R&D globalization and public sector linkages in Japanese firms in the 1990s:the case of electronics and pharmaceuticals[J].Management of Innovation and Technology,2000,1:253-258.
[41]Ning Chen,Shuo Huang.Pharmaceutical E-Business in China:a Case of a Pharmaceutical E-Commerce Company[J].Service Systems and Service Management,2006,1:361-367.